{"id":"W2951153020","doi":"10.1097/01.hs9.0000561560.35825.0d","title":"S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3‐YEAR UPDATE OF THE ECHELON‐1 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"ABVD; Dacarbazine; Procarbazine; Medicine; Brentuximab vedotin; Vinblastine; Bleomycin; Vincristine; Internal medicine; Oncology; Population; Chemotherapy; Lymphoma; Cyclophosphamide; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006258207,0.0004466952,0.001594574,0.0006935608,0.000210941,0.001813359,0.0008514917,0.0008749828,0.002671473],"category_scores_gemma":[0.003724935,0.0002717193,0.002091432,0.00134327,0.0002671385,0.001293394,0.0005988557,0.002044456,0.0006444421],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001568106,"about_ca_system_score_gemma":0.001381437,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001901028,"about_ca_topic_score_gemma":0.007098317,"domain_scores_codex":[0.9987759,0.0004564622,0.0001778235,0.0001044749,0.0003635169,0.0001218154],"domain_scores_gemma":[0.9960693,0.001088502,0.001247313,0.0001540058,0.0009785456,0.0004622379],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02478536,0.001253265,0.03949864,0.008931828,0.004842221,0.0002074547,0.0003500576,0.001813855,0.003796682,0.0013845,0.06715029,0.8459858],"study_design_scores_gemma":[0.03536105,0.03552003,0.2373811,0.01516841,0.01998004,0.002427014,0.0006070394,0.00339166,0.00416773,0.002897812,0.6428878,0.0002103415],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.2309892,0.7211917,0.00151246,0.01169452,0.002075224,0.0008430293,0.009787289,0.0001899336,0.02171655],"genre_scores_gemma":[0.5421652,0.3907399,0.004368471,0.03041142,0.002839197,0.001527611,0.02312895,0.0001904686,0.004628777],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.006258207,"threshold_uncertainty_score":0.03309697,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00953334348027245,"score_gpt":0.2523886075679352,"score_spread":0.2428552640876628,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}